TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01247636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance- training and home-exercise
Description: Balance-training admitted at the geriatric hospital Home-exercise or advice to be generally active

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance-training and home-exercise
Description: The aim of the intervention was to enhance health-related quality of life, self-efficacy and physical function through education and exercise. The education program consisted of information given both oral and in writing regarding the benefits of physical activity. The aim was to increase the participants knowledge about the benefits of physical activity and to stimulate them to integrate physical activity into their immediate environment during daily routines. They were given an exercise-log and were advised to write down all their daily activities and exercise. The exercise program were conducted 2 times per week for 45 min per session. The content of these sessions were balance training with main focus on balance-exercises considered essential for daily living.
Study: NCT03078374

Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin
Description: Reduced dosage to obtain lower INR range
Study: NCT01161043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor wear
Description: All subjects to wear sensors
Study: NCT01670539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HomMed Telemonitor
Description: A HomMed Telemonitor wireless telemonitoring system collects data on a daily basis, including heart rate, blood pressure, oxygen level, body temperature, weight, responses to 9 pre-programmed questions (including difficulty breathing, fatigue, limited activities, difficulty taking meds, pain). Telemonitored results are transmitted to the research office for analysis and contact to patient by clinical research nurses.
Study: NCT05223634

Intervention type: OTHER
Intervention: Collection of oral and/or nasal samples
Description: Collection of oral and/or nasal samples after SOC test performed
Study: NCT03280654

Intervention type: OTHER
Intervention: overactive bladder
Description: Association between groups and over active bladder symptoms

Intervention type: OTHER
Intervention: overactive bladder
Description: Association between groups and over active bladder symptoms
Study: NCT02783443

Intervention type: OTHER
Intervention: General anesthesia
Description: General anesthesia

Intervention type: OTHER
Intervention: Regional anesthesia
Description: Regional anesthesia
Study: NCT01648790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel ODT1 - Tablet
Description: Administered orally as tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel ODT2 - Tablet
Description: Administered orally as tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel ODT2 - Tablet
Description: Administered orally as tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel ODT2 - Tablet
Description: Administered orally as tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel ODT2 - Suspension
Description: Administered orally as suspension.
Study: NCT01232543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Product 0405
Description: Product 0405 will be administered topically, twice daily for 28 days.
Study: NCT02665052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-Based BATRAC plus TTT
Description: Home-based BATRAC training will consist of 60 minutes of training at home (45 minutes using the BATRAC and 15 minutes of TTT) using the BATRAC training will include high intensity bilateral reaching and rest periods using the BATRAC followed by 15 minutes of video guided transition to task training (TTT). These videos will be linked from the VA MyHealtheVet site to study specific Youtube videos of the study therapist demonstrating the exercise. Asynchronous communication between the therapist and participant will be completed using the MyHealtheVet secure messaging system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lab-based BATRAC plus TTT
Description: Lab-based BATRAC will consist of 60 minutes of training in the lab (45 minutes using BATRAC and 15 minutes of TTT). BATRAC training will include high intensity bilateral reaching and retrieving actions (pushing handles away and pulling them back) on a constrained linear track to promote maximum arm extension. This training will be followed by 15 minutes of transition to task training (TTT) with supervision and support as needed by the therapist.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Delayed Entry Usual Care
Description: Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions and weekly phone calls to record general activity level.
Study: NCT00424749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients received 4 weekly doses of rituximab 375 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 1 mg/kg/day (not to exceed 80 mg/day) for 4 weeks followed by a taper to 0 mg by 6 months
Study: NCT01257815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Study: NCT00938808

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: day formula diet
Description: The Cambridge Programme. Formula diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: day formula diet
Description: The Cambridge Programme. Formula diet
Study: NCT01990638

Intervention type: OTHER
Intervention: exercise capacity test

Intervention type: OTHER
Intervention: exercise capacity test
Study: NCT00446524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan + Amlodipine besilate
Description: During the run-in period, either Valsartan 80 mg or Amlodipine 5 mg tablet was given once daily. Throughout the Valsartan + Amlodipine treatment period, a Valsartan + Amlodipine tablet 80/5 mg was given once daily at around 8:00 AM in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan + Amlodipine besilate
Description: During the run-in period, either Valsartan 80 mg or Amlodipine 5 mg tablet was given once daily. Throughout the Valsartan + Amlodipine treatment period, a Valsartan + Amlodipine tablet 80/5 mg was given once daily at around 8:00 AM in the morning.
Study: NCT02584322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery pathway
Description: The enhanced recovery pathway consists of postoperative medical orders including nursing care, investigations and tests, and other peri-operative orders. The enhanced recovery pathway is standardized for all patients, and can be discontinued at any time when clinical judgment mandates (i.e. patient has a severe complication).
Study: NCT02709499

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 0J LLLT
Description: perform with the machine off

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6J LLLT
Description: irradiation will be perform with 4J
Study: NCT03390543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sono with Device
Description: In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, both the device and sono-guided internal jugular vein catheterization was performed.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sono only
Description: In Group S, simple needle guide device was not attached to the sono probe. After induction of anesthesia, only sono-guided internal jugular vein catheterization was performed.
Study: NCT03901105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flortaucipir F18
Description: No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) at baseline will be read by independent, blinded readers. IV injection, 240 megabecquerel (MBq) (6.5 mCi), single dose in AZES

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET Scan
Description: positron emission tomography (PET) scan of the brain
Study: NCT00619970

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Breath Test
Description: Healthy controls will receive one lactulose breath test to assess for SIBO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: xifaxan
Description: xifaxan 550mg TID x10days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo TID x 10days

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lactulose Breath Test
Description: Children with CAP will receive one lactulose breath test to assess for SIBO and one after receiving either Rifaximin or Placebo

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Breath Test
Description: Children with CAP will receive one lactulose breath test to assess for SIBO and one after receiving either Rifaximin or Placebo
Study: NCT01750320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Koning Breast CT-guided Biopsy
Description: The breast will be positioned and stabilized in the grid/compression device. Four KBCT scans will be taken to guide the vacuum-assisted biopsy procedure.
Study: NCT00520728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Time Use Intervention
Description: 12 week behavioral intervention administered by Occupational Therapists.
Study: NCT03789461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: FMT infusion (100-200ml) and Mucosal Microbiota Assessment (To assess the fecal and mucosal microbiota before and after FMT)
Study: NCT04029220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Peer Navigation
Description: Parent Peer Navigation (PPN) is implemented by trained providers with lived experience, who are supported by training and coaching protocols. The role of PPN provider is to engage caregivers in necessary treatment for their children and prepare them to independently navigate the child serving system, community-based resources, and ongoing opportunities for support. PPN providers will support families who are just entering he child-serving systems for 6 months on a weekly basis during which they will: help link families with formal and informal supports; instill confidence and coping skills; assist in the development of goals and crisis plans; and serve as an advocate for resolution of issues. Also, the PPN provider helps the family to learn to navigate systems and advocate for their needs, prepares families for meetings and treatment sessions, helps identify ways for parents to practice self-care; and promotes family choice and shared decision making.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Peer Navigation
Description: Parent Peer Navigation (PPN) is implemented by trained providers with lived experience, who are supported by training and coaching protocols. The role of PPN provider is to engage caregivers in necessary treatment for their children and prepare them to independently navigate the child serving system, community-based resources, and ongoing opportunities for support. PPN providers will support families who are just entering he child-serving systems for 6 months on a weekly basis during which they will: help link families with formal and informal supports; instill confidence and coping skills; assist in the development of goals and crisis plans; and serve as an advocate for resolution of issues. Also, the PPN provider helps the family to learn to navigate systems and advocate for their needs, prepares families for meetings and treatment sessions, helps identify ways for parents to practice self-care; and promotes family choice and shared decision making.
Study: NCT03868540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet
Study: NCT03434340

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peppermint essential oil
Description: 2 drops applied on a nasal strip

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: 1mg intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: 1mg intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 4mg intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4mg intravenous injection
Study: NCT03163251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: READ-SG Sessions
Description: In the Internal Medicine residency program at Columbia University Medical Center, PGY-1 trainees receive an hour of protected time to attend a monthly peer-facilitated small group session, outlined above. PGY-2 and 3 trainees have a similar combined session separate from the PGY-1s. Facilitators are chosen by the READ-SG Committee, which is comprised of Mark P. Abrams (Director, Co-Investigator), Evelyn Granieri (Faculty Advisor, PI), a Chief Resident from the program (Program Liaison), and the facilitators.
Study: NCT04862533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-Alanine
Description: Participants will receive 1150mg of beta-alanine three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo three times a day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Description: Participants in both groups will undergo PFMT training program

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Description: Participants in both groups will undergo PFMT training program
Study: NCT04042870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joint Loosening Yoga
Description: Sukshma Vyayama Joint Loosening Yoga was practiced Monday - Friday for four weeks. Each session included twelve joint loosening exercises performed in a chair, each performed 10 times with mindful awareness of physical movements and breath synchronization. Sessions lasted 15 minutes.
Study: NCT04206020

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SkQ1 Vehicle Solution
Description: SkQ1 Ophthalmic Solution Vehicle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SkQ1 Ophthalmic Solution
Description: SkQ1 Ophthalmic Solution
Study: NCT00572026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Transdermal System
Description: Daytrana wear time up to 15 hours
Study: NCT03714191

Intervention type: OTHER
Intervention: Patient Outcomes
Description: The intervention includes different versions of the BPA design and message.

Intervention type: OTHER
Intervention: Billing documentation
Description: The intervention includes different versions of the BPA design and message.

Intervention type: OTHER
Intervention: Regulatory
Description: The intervention includes different versions of the BPA design and message.
Study: NCT02775084

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: 4 capsules twice daily with food for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: 4 capsules twice daily with food for 6 weeks
Study: NCT00609193

Intervention type: DRUG
Intervention: lithium
Description: standard clinical care

Intervention type: DRUG
Intervention: quetiapine
Description: standard clinical care
Study: NCT02330575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The participant exercise sessions will be conducted in small groups of 5 to 10 participants under the direct supervision of the community-based exercise specialist. Participants will have the choice between taking part in a bridging exercise class (e.g., Beauty program and Bridging to Fitness - Cancer) or group-based supervised fitness centre exercise training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants allocated to the standard care group will receive standard advice and counseling on physical activity and will serve as the 'control group' for a 16-week period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants allocated to the standard care group will receive standard advice and counseling on physical activity and will serve as the 'control group' for a 16-week period.
Study: NCT01231659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10 mg (2 tablets of 5 mg) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg once daily
Study: NCT01314963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype intraoperative handheld gamma camera (pIHGC)
Description: The prototype intraoperative handheld gamma camera (pIHGC) consists of a parallel-hole lead collimator coupled to a pixilated sodium iodide-thallium \[NaI(Tl)\] scintillation crystal array, itself coupled to a flat panel, multi-anode Hamamatsu H8500 position-sensitive photomultiplier tube. The collimator is 5x5 cm2 large in area and 1.5 cm thick, with 1.3 mm hexagonal holes and 0.2 mm septa. The 1.7 mm pitch crystal array is composed of 29x29 individual crystals, each 1.5x1.5x6 mm3 in size.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphoscintigraphy with intraoperative gamma probes (GP)
Description: Lymphoscintigraphy with standard of care intraoperative gamma probes (GP)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radioactive Tc99M
Description: Lymphoscintigraphy involves injection of 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid around at the tumor site.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radioactive Tc99M
Description: Lymphoscintigraphy involves injection of 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid around at the tumor site.
Study: NCT02386748

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: Chewing sugarless gum after the discharge from the operating room by two hours for at least half an hour at two hours intervals.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral fluids
Description: Starting clear oral fluids after operating room discharge by six hours, then hearing intestinal sounds on second day before initiating full regular diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous fluids
Description: Women in this group will not receive neither gum nor oral fluids, they will be on intravenous fluids (lactated ringer solution).

Intervention type: OTHER
Group type: OTHER
Intervention: Intravenous fluids
Description: Women in this group will not receive neither gum nor oral fluids, they will be on intravenous fluids (lactated ringer solution).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fluids
Description: Women in this group will not receive neither gum nor oral fluids, they will be on intravenous fluids (lactated ringer solution).
Study: NCT03331861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride
Description: Metformin starting at 500mg twice a day and increasing to 1000mg twice a day for a total of 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar dosing regime as active comparator
Study: NCT03250260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-dimensional photograph with simulation
Description: The viewing of a 3-dimensional simulation is classed as an intervention as it strays from the normal pre-operative preparation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Viewing of a 2-dimensional photographic library
Description: The viewing of a 2-dimensional photograph library is classed as an intervention as it strays from the normal pre-operative preparation.
Study: NCT00113074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Nicotine replacement therapy program

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Nicotine replacement therapy program

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: Nicotine replacement therapy program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Diet program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Diet program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Diet program
Study: NCT04091490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Combination of 2 cycles of Nivolumab as a monotherapy with 4 cycles of high-dose chemotherapy (DHAP chemoregimen) with Nivolumab
Study: NCT03800784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL Injection
Description: A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
Study: NCT01578408

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented Lubinus SPII stem (control arm)
Description: Cemented Lubinus femoral stem. Cemented IP acetabular cup. (Link).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncemented HA Coated Corail stem
Description: Uncemented hydroxyapatite coated Corail femoral stem. Cemented Marathon acetabular cup. (DePuy).
Study: NCT00038727

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DPPOS Group Lifestyle
Description: Quarterly group lifestyle sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DPPOS Group Lifestyle
Description: Quarterly group lifestyle sessions

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: DPPOS Group Lifestyle
Description: Quarterly group lifestyle sessions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Administered as 850mg twice per day, masked in DPP and open label in DPPOS

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DPPOS Boost Lifestyle
Description: In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Lifestyle Group Session
Description: 16 session curriculum in group format. In DPP delivered to ILS as individual sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Lifestyle Group Session
Description: 16 session curriculum in group format. In DPP delivered to ILS as individual sessions

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Intensive Lifestyle Group Session
Description: 16 session curriculum in group format. In DPP delivered to ILS as individual sessions